CADL
Candel Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.05
+2.61%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- 75.04x
- P/S forward
- 39.84x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 5.49x
- Price / sales
- —
- Price / cash flow
- -12.36x
Enterprise value
- Enterprise value
- $540.4M
- EV / sales
- —
- EV / EBITDA
- -6.50x
- EV / EBIT
- -7.51x
- Market cap
- $692.5M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026